BofA Raises Pfizer Price Target After Strong Q1 Results

Bank of America (BofA) analysts have revised their price target for Pfizer (PFE) upward following the company's strong first-quarter financial results. The decision is linked to the company's quarterly performance exceeding expectations and maintaining a positive outlook for the future. Analysts noted that Pfizer's sales and profit figures for the first quarter surpassed market estimates, driven particularly by strong demand for its COVID-19 vaccine and treatment, as well as steady growth in its other drug portfolio. This also reflects the company's financial discipline and operational efficiency. In setting the new price target, BofA considered Pfizer's increased revenue potential and strong cash flow. Additionally, progress in the company's R&D pipeline and potential new product launches were highlighted as positive contributors to the stock's valuation. While investors closely monitor such corporate assessment updates, Pfizer shares are expected to follow a positive trajectory in the short term following this news. However, market conditions and sector dynamics remain among other factors that could influence the stock price. This is not investment advice.